RE: Data & Toxicity Concerns3 Mar 2024 21:43
Chemotherapy has advantages in the treatment of cancer. It will kill or cause cancers to mutate.
737 works in parallel with these cancer destroying agents in that it does not allow the multiplication and repair of DNA with strand breaks ie mutated DNA. Much of this is indicated by the control of Chk1 in at the P53 checkpoint. In this sense CHK1 can only limit new cell growth and has little effect in killing cancer tumours that already exist.
What a CHK1 inhibitor does is prevent the replication or production of cancerous cells at the point of reproduction.
Hence CHK1 inhibitors need to work in conjunction with other forms of cancer killing agents or distress caused in the formulation of new cancer cells at the point of mitosis ie cell division and replication.
The most important aspect in over half of cancers is the P53 checkpoint. In this instance l have never found in any shape or form an alternative that addresses this issue
We have WEE1 PARPi and PD-1 but they are also basically ineffective as a mono treatment albeit greater efficacy in combo with the like of Chemotherapy.
CHK 1 inhibitors therefore cannot be ignored as indicated by the resurgence of CHK1 inhibitors in combination therapy. How else do you control cancer cells growing if you do not address one of the most if not the most important areas of signalling pathways if you do not address it.
Later newer approaches made, along with generated hype to induce new therapies which are supposed to address all former problems with previous inhibitors that have not given an appropriate amount of attention to maximise the the potential of inhibitors we already have.
It's a money making game for the pharma that take on to feed their greed not to dissimilar to on going wars created by the West and the US in particular to gain masses on revenue from military weapons production.
Corporate bodies as well as military establishments as well as pharmas are corrupt and that is very easily identified as well those in government play a part which is financially beneficial to them.
I will end on stressing the importance of CHK1 in the treatment of certainly difficult to treat cancers.
Prexasertib which l feel inferior to 737 in that it has issues associated with mycocardia and hence was discontinued and in addition can only be administered intravenously.
However, this did not stop Acrivon taking it on board.
Regards and adding all the time.
Sign In
Follow the stocks
